蛋白酸酶2A anchoring破坏者为家族扩展性心肌病的基因疗法
Xueyi Li1, Jinliang Li1, Anne-Maj Samuelsson1
1Stanford Cardiovascular Institute, Departments of Ophthalmology and Medicine, Stanford University, Palo Alto, CA 94304, USA.
Molecular therapy. Methods & clinical development
|April 4, 2024
概括
使用AAV9sc.PBD的基因治疗成功地改善了家族扩张性心肌病小鼠模型中的心脏结构和功能. 这种方法针对PP2A酸酶定,为心力衰竭提供潜在的广泛治疗.
科学领域:
- 心血管生物学 心血管生物学
- 基因治疗 基因治疗
- 分子心脏病学分子心脏病学
背景情况:
- 亲属扩张性心肌病 (DCM) 是心力衰竭和心脏移植的主要原因.
- 在DCM中病理性心脏重塑与心肌细胞周核mAKAPβ信号体中的蛋白酸酶2A (PP2A) 活性有关.
- 目前DCM的治疗方法的疗效有限,这凸显了需要新的治疗策略的需要.
研究的目的:
- 调查是否破坏PP2A对mAKAPβ的定可以防止DCM相关的心脏功能障碍.
- 评估AAV9sc.PBD基因疗法的治疗潜力在家族DCM的小鼠模型中.
主要方法:
- 开发一种腺相关病毒基因治疗载体 (AAV9sc.PBD),将PP2A结合域传递给心肌细胞.
- 使用表达突变α-tropomyosin E54K (Tpm1) 等位基因的转基因小鼠模型来模仿家族DCM.
- 在治疗和对照小鼠中评估心脏结构,功能,心肌细胞形态和基因表达.
主要成果:
- 在突变Tpm1DCM小鼠模型中,AAV9sc.PBD的使用显著改善了心脏结构和功能.
- 基因疗法载体在正常,非转基因小鼠中对心脏参数没有显示任何不良影响.
- 在细胞水平上,AAV9sc.PBD治疗恢复了心肌细胞形态,并在DCM小鼠模型中使基因表达正常化.
结论:
- 通过AAV9sc.PBD破坏PP2A的定是预防和治疗DCM相关心脏功能障碍的可行策略.
- 这些发现支持AAV9sc.PBD作为扩张性心肌病的潜在广泛治疗剂,无论具体的遗传原因如何.
- 根据这一概念验证研究,对AAV9sc.PBD进行DCM治疗的进一步临床研究是有必要的.
相关概念视频
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
162
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
162
01:21Satellite Stem Cells and Muscular Dystrophy
2.0K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.0K